References:
1.
Yang
MH, Wan WQ, Luo JS, Zheng MC, Huang K, Yang LH, et al. Multicenter
randomized trial of arsenic trioxide and Realgar-Indigo naturalis
formula in pediatric patients with acute promyelocytic leukemia: Interim
results of the SCCLG-APL clinical study. Am J Hematol
2018;93(12):1467-1473.
2. Zhu
HH, Wu DP, Jin J, Li JY, Ma J, Wang JX, et al. Oral tetra-arsenic
tetra-sulfide formula versus intravenous arsenic trioxide as first-line
treatment of acute promyelocytic leukemia: a multicenter randomized
controlled trial. J Clin Oncol 2013;31(33):4215-21.
3.
Kutny
MA, Alonzo TA, Gerbing RB, Wang YC, Raimondi SC, Hirsch BA, et al.
Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for
Pediatric Patients With Acute Promyelocytic Leukemia: Report From the
Children’s Oncology Group Phase III Historically Controlled Trial
AAML0631. J Clin Oncol 2017;35(26):3021-3029.
4.
Iland
HJPC, Group ALAL. Use of arsenic trioxide in remission induction and
consolidation therapy for acute promyelocytic Leukemia in the
Australasian Leukemia and Lymphoma Group (ALLG) APML4 study: a
non-randomised phase 2 trial. Lancet Haematol 2015;2(9):e357 - e366.
5.
Kayser
S, Schlenk RF, Platzbecker U. Management of patients with acute
promyelocytic leukemia. Leukemia 2018;32(6):1277-1294.
6.
Wang
L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, et al. Dissection of
mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an
effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A
2008;105(12):4826-31.
7. Zhu
H, Guo Z, Jia J, Jiang Q, Jiang H, Huang X. The impact of oral arsenic
and all-trans-retinoic acid on coagulopathy in acute promyelocytic
leukemia. Leukemia Research 2018;65:14-19.
8.
Wang
F, Jia J, Wang J, Zhao T, Jiang Q, Jiang H, et al. The kinetics of white
blood cell and the predictive factors of leukocytosis under oral or
intravenous arsenic as the first-line treatment for acute promyelocytic
leukemia. Leukemia Research 2017;61:84-88.
9.
Kutny
MA, Gregory J, Feusner JH. Treatment of paediatric APL: How does the
therapeutic approach differ from adults? Best Practice & Research
Clinical Haematology 2014;27(1):69-78.
10.
Creutzig
U, Dworzak MN, Bochennek K, Faber J, Flotho C, Graf N, et al. First
experience of the AML-Berlin-Frankfurt-Munster group in pediatric
patients with standard-risk acute promyelocytic leukemia treated with
arsenic trioxide and all-trans retinoid acid. Pediatr Blood Cancer
2017;64(8).
11.
Platzbecker
U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, et al.
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With
Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic
Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Journal of Clinical Oncology 2017;35(6):605-612.
12.
Lo-Coco
F AGVM, dell’Adulto GIME, Group GAML, Leukemia SA. Retinoic Acid and
Arsenic Trioxide for Acute Promyelocytic Leukemia. N Engl J Med
2013;369:111-21.
13.
Zhang
L, Zou Y, Chen Y, Guo Y, Yang W, Chen X, et al. Role of cytarabine in
paediatric acute promyelocytic leukemia treated with the combination of
all-trans retinoic acid and arsenic trioxide: a randomized controlled
trial. BMC Cancer 2018;18(1):374.
14.
Zhu
HH, Huang XJ. Oral arsenic and retinoic acid for non-high-risk acute
promyelocytic leukemia. N Engl J Med 2014;371(23):2239-41.
15.
Zhu
HH, Wu DP, Du X, Zhang X, Liu L, Ma J, et al. Oral arsenic plus retinoic
acid versus intravenous arsenic plus retinoic acid for non-high-risk
acute promyelocytic Leukemia: a non-inferiority, randomised phase 3
trial. Lancet Oncol 2018;19(7):871-879.
16.
Chen
GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, et al. Use of arsenic
trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL):
I. As2O3 exerts dose-dependent dual effects on APL cells. Blood
1997;89(9):3345-53.
17.
Abedin
S, Altman JK. Acute promyelocytic leukemia: preventing early
complications and late toxicities. Hematology Am Soc Hematol Educ
Program 2016;2016(1):10-15.
18.
Zheng
H, Jiang H, Hu S, Liao N, Shen D, Tian X, et al. Arsenic Combined With
All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia:
Report From the CCLG-APL2016 Protocol Study. J Clin Oncol
2021:JCO2003096.
19.
Tallman
MS, Altman JK. How I treat acute promyelocytic leukemia. Blood
2009;114(25):5126-35.
20. Ossenkoppele G, Schuurhuis GJ. MRD in AML: does it already guide
therapy decision-making? Hematology Am Soc Hematol Educ Program. 2016
Dec 2;2016(1):356-365.
21. Benjamini O, Dumlao TL, Kantarjian H, O’Brien S, Garcia-Manero G,
Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P,
Champlin R, Jabbour E, Burger J, Cortes J, Ravandi F. Phase II trial of
hyper CVAD and dasatinib in patients with relapsed Philadelphia
chromosome positive acute lymphoblastic leukemia or blast phase chronic
myeloid leukemia. Am J Hematol. 2014 Mar;89(3):282-7.